::A pentacyclic triterpenoid produced from medicinal herbs, fruits, and vegetables,
Ursolic acid (UA) has pharmacological activity. This review provides a comprehensive
overview of the interactions of UA with molecular targets, its various mechanisms of action,
and its clinical implications in cancer therapy. Numerous studies have been conducted
on the pharmacological effects of UA, and its biological benefits, such as its antiinflammatory,
antioxidant, and anti-cancer activities, have been demonstrated. The study
showed how signaling pathways, such as PI3K/Akt, MAPK, and NF-κB, work together to
control cell death, proliferation, and inflammation. UA effectively treats cancer by interacting
with molecular targets in cell signaling pathways, making it a potent treatment option. It
inhibits tumor cell transformation, limits their reproduction ability, and triggers apoptosis. It
also has been found to inhibit various pro-inflammatory transcription factors and cell cycle proteins, such as
kinases, cytokines, chemokines, adhesion molecules, and inflammatory enzymes. The targets may aid in UA's
chemopreventive and therapeutic benefits by preventing cancer initiation, growth, and metastasis. UA inhibits
cancer cell proliferation by arresting and triggering apoptosis through the cell cycle. It is a promising anticancer
agent with various mechanisms of action. Additionally, it can target multiple signaling pathways and
influence the tumor microenvironment, suggesting its potential as a complementary therapy in cancer treatment.
Further clinical investigations are needed to entirely understand the therapeutic potential of UA and optimize its
application in cancer. This review explores the molecular targets of UA and provides insights into its potential
anticancer activities.